{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:06:10Z","timestamp":1793419570939,"version":"4.5.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in Alcoholism (BIMA) study. This is the first MDMA addiction study, an open-label safety and tolerability proof-of-concept study investigating the potential role for MDMA therapy in treating patients with alcohol use disorder (AUD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study aimed to assess if MDMA-assisted psychotherapy can be delivered safely and can be tolerated by patients with AUD post detoxification. Outcomes regarding drinking behaviour, quality of life and psychosocial functioning were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Fourteen patients with AUD completed a community alcohol detoxification and received an eight-week course of recovery-based therapy. Participants received two sessions with MDMA (187.5\u2009mg each session). Psychological support was provided before, during and after each session. Safety and tolerability were assessed alongside psychological and physiological outcome measures. Alcohol use behaviour, mental well-being and functioning data were collected for nine months after alcohol detoxification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>MDMA treatment was well tolerated by all participants. No unexpected adverse events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol use, at nine months post detox, the average units of alcohol consumption by participants was 18.7\u2009units per week compared to 130.6 units per week before the detox. This compares favourably to a previous observational study (the \u2018Outcomes\u2019 study) by the same team with a similar population of people with AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study provides preliminary support for the safety and tolerability of a novel intervention for AUD post detox. Further trials to examine better the therapeutic potential of this approach are now indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0269881121991792","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T03:28:54Z","timestamp":1613878134000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":109,"title":["First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1212-6060","authenticated-orcid":false,"given":"Ben","family":"Sessa","sequence":"first","affiliation":[{"name":"Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Higbed","sequence":"additional","affiliation":[{"name":"Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Durant","sequence":"additional","affiliation":[{"name":"Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Sakal","sequence":"additional","affiliation":[{"name":"Drug Science, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Titheradge","sequence":"additional","affiliation":[{"name":"School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim M","family":"Williams","sequence":"additional","affiliation":[{"name":"Avon and Wiltshire NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rose-Morris","sequence":"additional","affiliation":[{"name":"Avon and Wiltshire NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Brew-Girard","sequence":"additional","affiliation":[{"name":"Avon and Wiltshire NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Burrows","sequence":"additional","affiliation":[{"name":"Avon and Wiltshire NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-3969","authenticated-orcid":false,"given":"Chantelle","family":"Wiseman","sequence":"additional","affiliation":[{"name":"Centre for Academic Mental Health, School of Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Wilson","sequence":"additional","affiliation":[{"name":"Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rickard","sequence":"additional","affiliation":[{"name":"Biotherapy Services, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Nutt","sequence":"additional","affiliation":[{"name":"Imperial College London, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, London, UK"},{"name":"Drug Science, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"bibr1-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"bibr2-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"bibr3-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.12.015"},{"key":"bibr4-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713001405"},{"key":"bibr5-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30222-6"},{"key":"bibr6-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30088-8"},{"key":"bibr7-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1998.10399713"},{"key":"bibr8-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09040458"},{"key":"bibr9-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1080\/13803390903042361"},{"key":"bibr10-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1131-1"},{"key":"bibr11-0269881121991792","doi-asserted-by":"publisher","DOI":"10.2174\/18744737112059990005"},{"key":"bibr12-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2006.00013.x"},{"key":"bibr13-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0321-7"},{"key":"bibr14-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112444324"},{"key":"bibr15-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1080\/08897070903250027"},{"key":"bibr16-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00019.x"},{"key":"bibr17-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5"},{"key":"bibr18-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371"},{"key":"bibr19-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112456611"},{"key":"bibr20-0269881121991792","unstructured":"NICE (2011) Alcohol-use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. NICE clinical guideline 115. Available at: www.nice.org.uk\/CG115 (accessed 1 June 2020)."},{"key":"bibr21-0269881121991792","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S45666"},{"key":"bibr22-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03912.x"},{"key":"bibr23-0269881121991792","author":"R\u00f6sner S","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr24-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.050344"},{"key":"bibr25-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.11.004"},{"key":"bibr26-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.148031"},{"key":"bibr27-0269881121991792","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00138"},{"key":"bibr28-0269881121991792","volume":"6","author":"Sessa B","year":"2020","journal-title":"J Alcohol Drug Depend Subst Abuse"},{"key":"bibr29-0269881121991792","doi-asserted-by":"publisher","DOI":"10.2174\/1874473710801030280"},{"key":"bibr30-0269881121991792","doi-asserted-by":"crossref","unstructured":"Stolaroff M (2004) The Secret Chief Revealed: Conversations with a Pioneer of the Underground Therapy Movement. Sarasota: Multidisciplinary Association for Psychedelic Studies, pp.45\u201349.","DOI":"10.4324\/9780203352069-10"},{"key":"bibr31-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106060764"},{"key":"bibr32-0269881121991792","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7516.541"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881121991792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881121991792","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881121991792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:10:52Z","timestamp":1777507852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881121991792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/0269881121991792"],"URL":"https:\/\/doi.org\/10.1177\/0269881121991792","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}